Eteplirsen

DRUG7 trials

Sponsors

Sarepta Therapeutics, Inc.

Conditions

Duchenne Muscular DystrophyDuchenne Muscular Dystrophy (DMD)Muscular Dystrophy, Duchenne

Phase 2

Safety Study of Eteplirsen to Treat Advanced Stage Duchenne Muscular Dystrophy

CompletedNCT02286947

Sarepta Therapeutics, Inc.Muscular Dystrophy, Duchenne

Start: 2014-11-30End: 2018-03-23Updated: 2020-03-30

Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy

CompletedNCT02420379

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy (DMD)

Start: 2015-06-30End: 2018-12-17Updated: 2021-01-25

Study of Eteplirsen in Young Participants With Duchenne Muscular Dystrophy (DMD) Amenable to Exon 51 Skipping

CompletedNCT03218995

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2017-08-16End: 2021-03-10Updated: 2021-12-09

A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) Who Have Completed Study 4658-102 (NCT03218995)

TerminatedNCT03985878

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2019-06-26End: 2022-08-31Updated: 2023-08-18

Phase 3

Study of Eteplirsen in DMD Patients

CompletedNCT02255552

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy (DMD)

Start: 2014-11-17End: 2019-06-14Updated: 2021-01-25

A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)

Active, not recruitingNCT03992430

Sarepta Therapeutics, Inc.Muscular Dystrophy, Duchenne

Start: 2020-07-13End: 2026-10-31Updated: 2026-02-27

Unknown Phase

A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice

Enrolling by invitationNCT06606340

Sarepta Therapeutics, Inc.Duchenne Muscular Dystrophy

Start: 2019-01-07End: 2033-12-31Target: 300Updated: 2025-09-10

Related Papers

Advancements from the EVOLVE study for assessing real-world experience with eteplirsen, golodirsen and casimersen for the treatment of DMD.

2026-04-10

Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6-48 months with Duchenne muscular dystrophy amenable to exon 51 skipping.

2023-03-2418 citations